SCHEMBL5230860

SCHEMBL5230860

Cc1ccccc1-c1nc(N2CCN(S(C)(=O)=O)CC2)nc2c1C(=O)N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)CCCN2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 12/20 0.41
GPBAR1 Q8TDU6 1/20 0.40
SMO Q99835 2/20 0.37
CYP2D6 P10635 1/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
CASP1 P29466 1/20 0.34
CASP5 P51878 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
IDO1 P14902 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5225834 0.91 TACR1 (0.44) TACR1GPBAR1CASP1CASP5PSEN1
SCHEMBL5232346 0.90 TACR1 (0.42) TACR1GPBAR1CASP1CASP5PSEN1
SCHEMBL5232238 0.89 TACR1 (0.43) TACR1TSHRCASP1CASP5PSEN1
SCHEMBL5232458 0.89 TACR1 (0.40) TACR1GPBAR1MEN1TSHRKMT2A
SCHEMBL5228486 0.88 TACR1 (0.44) TACR1SMOCYP2D6CYP1A2CYP3A4
SCHEMBL5232740 0.88 TACR1 (0.42) TACR1CASP1CASP5PSEN1PSEN2
SCHEMBL5230354 0.88 SMO (0.40) TACR1SMOTSHRKMT2APSEN1
SCHEMBL5233229 0.87 TACR1 (0.42) TACR1CYP3A4PSEN1PSEN2APH1B
SCHEMBL5227311 0.86 TACR1 (0.42) TACR1SMOCYP2D6CYP1A2CYP3A4
SCHEMBL5225462 0.86 SDHB (0.40) TACR1GPBAR1PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1496059-B1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES KYORIN SEIYAKU KK (JP) 2007-08-15 EP disclosed
EP-1496059-B1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES KYORIN SEIYAKU KK (JP) 2007-08-15 EP disclosed
US-7064119-B2 Fused bicyclic pyrimidine derivatives KYORIN PHARMACEUTICAL CO., LTD. (JP) 2006-06-20 US disclosed
US-20050159409-A1 Fused bicyclic pyrimidine derivatives KYORIN PHARMACEUTICAL CO. LTD. (JP) 2005-07-21 US disclosed
EP-1496059-A1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES Kyorin Pharmaceutical Co., Ltd. (JP) 2005-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159409-A1 Fused bicyclic pyrimidine derivatives BDKRB1, BDKRB2, TACR1 TACR1 3/4885GPBAR1 311/4885SMO 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.